7 results
Mechanism of Action for Common Diabetes Medications

 • SGLT2i (Dapagliflozin)
 • TZD (Pioglitazone)
 • Biguanides (Metformin)
Action for Common Diabetes ... Receptor Agonists • DPP4i ... sarahthelyon #Diabetes ... #pathophysiology ... #endocrinology
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... events TZDs DPP ... EricsMedicalLectures/featured #diabetes ... #medications #table ... comparison #management #endocrinology
Euglycemic Diabetic Ketoacidosis (EuDKA)
SGLT2 Inhibitors
Increasing Indications
Significant Adverse Drug Effects
Definition of EuDKA
 • Metabolic acidosis with pH
Euglycemic Diabetic ... Ketoacidosis (EuDKA ... level < 200 mg/dL Pathophysiology ... #Euglycemic #Diabetic ... diagnosis #management #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Sulfonylurea, TZD, DPP ... insulin in Type 1 Diabetes ... monitors in Type 1 Diabetes ... pocketcardset #Diabetes
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... different than other medications ... very tolerable medication ... Pharmacology #Management #Diabetes ... #DM2 #Endocrinology
Diabetic Ketoacidosis (DKA) - Pathogenesis and Clinical Findings
 • Note: in DKA, body K+ is lost
Diabetic Ketoacidosis ... patient has good renal ... DiabeticKetoacidosis #DKA #pathophysiology ... #endocrinology ... #diabetes
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... drug to remain stable ... empagliflozin and DPP4 ... #semaglutide #Diabetes ... #Pharmacology #Endocrinology